1-11 of 11
Diego Vieyra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Free
María-Victoria Mateos, Nizar Bahlis, Aurore Perrot, Ajay Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne Mylin, Charlotte Hansen, Raphael Teipel, Britta Besemer, Meletios Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang-Ki Min, Paulus Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O'Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Luciano Costa
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2025-LBA-6
Published: 2025
Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Free
Francesco Corrado, Nayda Bidikian, Anna Bosch-Vilaseca, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Ting Wu, Sophie Magidson, Lorena Pantano, Michelle Aranha, Elizabeth Lightbody, Joseph Flinn, Michael Timonian, David Cordas Dos Santos, Rocio Montes De Oca, Tamar Lengil, Diego Vieyra, Mark Wildgust, Vicki Plaks, Denise De Wiest, Kevin De Braganca, Shonali Midha, Elizabeth O'Donnell, Yuxin Liu, Ashlee Sturtevant, Kenneth Anderson, Nikhil Munshi, Jerome Ritz, Omar Nadeem, Gad Getz, Romanos Sklavenitis-Pistofidis, Irene Ghobrial
Journal: Blood
Blood (2025) 146 (Supplement 1): 921.
https://doi.org/10.1182/blood-2025-921
Published: 2025
Journal Articles

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Free
David Cordas Dos Santos, Kane Foster, Daniel Heilpern-Mallory, Sophia Schroeder, Yoshinobu Konishi, Maria-Theresa Silverio, Jacqueline Perry, Sophie Magidson, Diego Vieyra, Rocio Montes De Oca, Daniel Zangrando, Nina Lane, Adam Sperling, Eric Smith, Jacob Laubach, Elizabeth O'Donnell, Nikhil Munshi, Kenneth Anderson, Shonali Midha, Gad Getz, Omar Nadeem, Irene Ghobrial
Journal: Blood
Blood (2025) 146 (Supplement 1): 3921.
https://doi.org/10.1182/blood-2025-3921
Published: 2025
Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Free
Peter Voorhees, Meletios Dimopoulos, Yaël Cohen, Fredrik Schjesvold, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Hila Magen, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špička, Anne Mylin, Simon Hallam, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew Cowan, Philippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Ashta Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, S. Vincent Rajkumar
Journal: Blood
Blood (2025) 146 (Supplement 1): 372.
https://doi.org/10.1182/blood-2025-372
Published: 2025
Journal Articles

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Open Access
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Evangelos Terpos, Mattia D'Agostino, Vincent H.J. van der Velden, Niels W.C.J. van de Donk, Michel Delforge, Christoph Driessen, Roman Hajek, Hermann Einsele, Annette Juul Vangsted, Diego Vieyra, Ricardo M Attar, Anna Sitthi-Amorn, Robin Carson, Fredrik Schjesvold, Pawel Robak, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Mario Boccadoro, Pieter Sonneveld
Journal: Blood
Blood blood.2025030113.
https://doi.org/10.1182/blood.2025030113
Published: 2025
Includes: Supplemental data
Journal Articles

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Available to Purchase
Clinical Trials & Observations
Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew W. Jenner, Dean Smith, Michele Cavo, Niels W. C. J. van de Donk, Meral Beksac, Philippe Moreau, Hartmut Goldschmidt, Diego Vieyra, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, Craig C. Hofmeister
Journal: Blood
Blood (2025) 145 (15): 1658–1669.
https://doi.org/10.1182/blood.2024025897
Published: 2025
Includes: Supplemental data
Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Free
Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 4757.1.
https://doi.org/10.1182/blood-2024-199752
Published: 2024
Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Free
Luca Bertamini, Cathelijne Fokkema, Paula Rodríguez-Otero, Mark van Duin, Niels W.C.J. Van De Donk, Mattia D'Agostino, Evangelos Terpos, Diego Vieyra, Ricardo M. Attar, Anna Sitthi-Amorn, Robin Carson, Michel Delforge, Christoph Driessen, Roman Hajek, Mario Boccadoro, Hermann Einsele, Annette Vangsted, Vincent H.J. Van Der Velden, Fredrik Schjesvold, Artur Jurczyszyn, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Pieter Sonneveld
Journal: Blood
Blood (2024) 144 (Supplement 1): 487.
https://doi.org/10.1182/blood-2024-199550
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Free
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2023-191911
Published: 2023
Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Free
Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4418–4419.
https://doi.org/10.1182/blood-2022-162733
Published: 2022
Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Free
Christie P.M. Verkleij, Kristine A. Frerichs, Carolien Duetz, Sonja Zweegman, Paola M. Homan-Weert, Monique C. Minnema, Annemiek Broyl, Mark-David Levin, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Maria Krevvata, Tineke Casneuf, Yann Abraham, Raluca I. Verona, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Diego Vieyra, Pieter Sonneveld, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Blood
Blood (2021) 138 (Supplement 1): 728.
https://doi.org/10.1182/blood-2021-150913
Published: 2021